Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 121Breast Neoplasms 83Colorectal Neoplasms 52Stomach Neoplasms 42Pancreatic Neoplasms 42Lung Neoplasms 41Rectal Neoplasms 38Neoplasm Metastasis 36Neoplasms 33Esophageal Squamous Cell Carcinoma 32Esophageal Neoplasms 31Head and Neck Neoplasms 26Squamous Cell Carcinoma of Head and Neck 23Ovarian Neoplasms 23Triple Negative Breast Neoplasms 21Nasopharyngeal Carcinoma 20Recurrence 18Leukemia, Myeloid, Acute 18Colonic Neoplasms 18Uterine Cervical Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Small Cell Lung Carcinoma 15Glioblastoma 15Lymphoma 12Prostatic Neoplasms 11Fallopian Tube Neoplasms 11Carcinoma, Squamous Cell 11Brain Neoplasms 11Sarcoma 10NSCLC 9

Interventions

pembrolizumab 3atezolizumab 2Sugammadex 2Saline Solution 2Paclitaxel 2Neostigmine 2Gemcitabine 2Cetuximab 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1tislelizumab 1testosterone 17 beta-cypionate 1temsirolimus 1relatlimab 1poly ICLC 1lenvatinib 1galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20 1delta 24-sterol reductase 1daratumumab 1cabozantinib 1abemaciclib 1Zoledronic Acid 1Water 1Valproic Acid 1Urinary Diversion 1Ultrasonography 1Trastuzumab 1Tomography, Optical Coherence 1Tissue Banks 1Therapeutics 1Testosterone Propionate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Urologic Neoplasms × Drug Therapy × Clear all
NCT06427057 2024-05-23

A Study of Cadonilimab(AK104)Combined With Standard Treatment for Function Preservation in Urinary System Tumors

Tongji Hospital

Phase 2 Not yet recruiting
40 enrolled
Genitourinary

Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡